<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Contemp Oncol (Pozn)</journal-id><journal-id journal-id-type="iso-abbrev">Contemp Oncol (Pozn)</journal-id><journal-id journal-id-type="publisher-id">WO</journal-id><journal-title-group><journal-title>Contemporary Oncology</journal-title></journal-title-group><issn pub-type="ppub">1428-2526</issn><issn pub-type="epub">1897-4309</issn><publisher><publisher-name>Termedia Publishing House</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28435404</article-id><article-id pub-id-type="pmc">5385483</article-id><article-id pub-id-type="publisher-id">29666</article-id><article-id pub-id-type="doi">10.5114/wo.2017.66661</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Paper</subject></subj-group></article-categories><title-group><article-title>Phase II study of adjuvant docetaxel and carboplatin with/without doxorubicin and cyclophosphamide in triple negative breast cancer: a randomised controlled clinical trial</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Najafi</surname><given-names>Safa</given-names></name><xref ref-type="aff" rid="aff0001">1</xref></contrib><contrib contrib-type="author"><name><surname>Payandeh</surname><given-names>Mehrdad</given-names></name><xref ref-type="aff" rid="aff0002">2</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Sadeghi</surname><given-names>Masoud</given-names></name><xref ref-type="aff" rid="aff0003">3</xref></contrib><contrib contrib-type="author"><name><surname>Shafaei</surname><given-names>Vahideh</given-names></name><xref ref-type="aff" rid="aff0001">1</xref></contrib><contrib contrib-type="author"><name><surname>Shojaiyan</surname><given-names>Fateme</given-names></name><xref ref-type="aff" rid="aff0001">1</xref></contrib><contrib contrib-type="author"><name><surname>Abbasvandi</surname><given-names>Fereshte</given-names></name><xref ref-type="aff" rid="aff0001">1</xref></contrib></contrib-group><aff id="aff0001"><label>1</label>Breast Cancer Research Center, ACECR, Tehran, Iran</aff><aff id="aff0002"><label>2</label>Department of Hematology and Medical Oncology, Kermanshah University of Medical Sciences, Kermanshah, Iran</aff><aff id="aff0003"><label>3</label>Medical Biology Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran</aff><author-notes><corresp id="cor1"><bold>Address for correspondence: Masoud Sadeghi</bold>, Medical Biology Research Center, Kermanshah University of Medical Sciences, 67145-1673 Kermanshah, Iran. e-mail: <email xlink:href="sadeghi_mbrc@yahoo.com">sadeghi_mbrc@yahoo.com</email></corresp></author-notes><pub-date pub-type="epub"><day>22</day><month>3</month><year>2017</year></pub-date><pub-date pub-type="ppub"><year>2017</year></pub-date><volume>21</volume><issue>1</issue><fpage>83</fpage><lpage>89</lpage><history><date date-type="received"><day>08</day><month>12</month><year>2016</year></date><date date-type="accepted"><day>29</day><month>1</month><year>2017</year></date></history><permissions><copyright-statement>Copyright: &#x000a9; 2017 Termedia Sp. z o. o.</copyright-statement><copyright-year>2017</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/4.0/"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.</license-p></license></permissions><abstract><sec id="s1"><title>Aim of the study</title><p>The aim of this trial was to compare overall survival (OS), disease-free survival (DFS), and toxicity of two adjuvant regimens in triple negative patients with Iranian ethnicity.</p></sec><sec id="s2"><title>Material and methods</title><p>In a phase II trial, patients with previously untreated triple negative breaststroke cancer were randomly assigned by using docetaxel 70 mg/m<sup>2</sup> and carboplatin AUC = 7 every three weeks with granulocyte colony-stimulating factor for sin courses (arm A) or doxorubicin hydrochloride 60 mg/m<sup>2</sup> and cyclophosphamide 600 mg/m<sup>2</sup> every three weeks with G-CSF for four courses followed by docetaxel 70 mg/m<sup>2</sup> and carboplatin AUC = 7 every three weeks with G-CSF for four courses (arm B).</p></sec><sec id="s3"><title>Results</title><p>A total of 119 patients were randomly enrolled in our study (60 patients in Arm A and 59 patients in Arm B) between 2011 and 2016. The mean follow-up was 40 months at the time of treatment analysis. The 2-year and 5-year DFS rates for Arm A were 92.7% vs. 85% and for Arm B were 82.6% vs. 64.4%. The 2-year and 5-year OS rates for Arm A were 96.5% vs. 91.7% and for Arm B were 90.5% vs. 81.3%. There was a significant correlation for DFS and OS in the two arms. There was no significant difference between adverse events with the two regimens.</p></sec><sec id="s4"><title>Conclusions</title><p>In our research, less progression was found with Arm A as compared to Arm B. Adding of anthracyclines such as doxorubicin hydrochloride did not increase OS and DFS in triple negative breast cancer (TNBC) patients.</p></sec></abstract><kwd-group><kwd>breast cancer</kwd><kwd>triple negative</kwd><kwd>carboplatin</kwd><kwd>docetaxel</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="sec1"><title>Introduction</title><p>Breast cancer (BC) is a chemosensitive tumour, and anthracyclines are among the most active cytotoxic agents in chemotherapy treatment [<xref rid="cit0001" ref-type="bibr">1</xref>]. Triple-negative breast cancer (TNBC) is diagnosed more frequently in younger and premenopausal women [<xref rid="cit0002" ref-type="bibr">2</xref>, <xref rid="cit0003" ref-type="bibr">3</xref>], comprising 15&#x02013;20% of all BCs [<xref rid="cit0003" ref-type="bibr">3</xref>, <xref rid="cit0004" ref-type="bibr">4</xref>], and is defined by the lack of oestrogen and progesterone receptor expression and also human epidermal growth factor receptor 2(HER2) amplification [<xref rid="cit0004" ref-type="bibr">4</xref>, <xref rid="cit0005" ref-type="bibr">5</xref>]. Chemotherapy is the basic treatment option for TNBC patients in the neoadjuvant, adjuvant, or metastatic settings. Despite the rather aggressive clinical behaviour of TNBC, about 30&#x02013;40% of patients achieve a pathological complete response (CR) with no histological evidence of disease at the time of surgery after neoadjuvant chemotherapy, and those patients have much higher rates of survival [<xref rid="cit0006" ref-type="bibr">6</xref>, <xref rid="cit0007" ref-type="bibr">7</xref>]. The differences in clinical response and survival after neoadjuvant chemotherapy suggest that a subset of TNBC may be inherently insensitive to cytotoxic chemotherapy [<xref rid="cit0008" ref-type="bibr">8</xref>]. Systemic adjuvant treatment with chemotherapy is almost always indicated [<xref rid="cit0009" ref-type="bibr">9</xref>]. Adjuvant therapy aids surgery in affecting cure of BC. Adjuvant treatments for BC can include chemotherapy, hormonal therapy, HER2-directed therapies, and radiation [<xref rid="cit0010" ref-type="bibr">10</xref>]. Adjuvant therapy for BC increases progression-free survival (PFS) and overall survival (OS), but does not benefit all BC patients [<xref rid="cit0011" ref-type="bibr">11</xref>]. Anthracyclines [<xref rid="cit0012" ref-type="bibr">12</xref>, <xref rid="cit0013" ref-type="bibr">13</xref>] and taxanes [<xref rid="cit0013" ref-type="bibr">13</xref>] are the most active and widely used chemotherapeutic agents for BC, but few data on the role of anthracyclines are available [<xref rid="cit0014" ref-type="bibr">14</xref>]. Anthracyclines are the drug class most closely associated with acute and late cardiac toxicity [<xref rid="cit0015" ref-type="bibr">15</xref>]. Herein, we reported the efficacy of adjuvant docetaxel and carboplatin with or without doxorubicin hydrochloride and cyclophosphamide in treating women with stage I&#x02013;III triple negative BC in Iran.</p></sec><sec sec-type="material|methods" id="sec2"><title>Material and methods</title><sec id="sec2.1"><title>Participants</title><p>This randomised phase II clinical trial was approved by the Ethics Committee of Kermanshah University of Medical Sciences, Kermanshah, Iran, and registered at <ext-link ext-link-type="uri" xlink:href="http://www.irct.ir">http://www.irct.ir</ext-link> (registration number: IRCT2016070325791N2). The range of participants&#x02019; recruitment was from Feb 2011 to Jul 2011. During Aug 2011 to Sep 2016 the patients referred to the Breast Cancer Research Centre, Tehran University of Medical Sciences, Tehran, Iran. All patients gave written, informed consent before enrolment. <xref ref-type="fig" rid="f0001">Figure 1</xref> shows the consort flow chart, which details the number of participants. The patients were divided into two groups: 60 patients in Arm A, treated with adjuvant docetaxel 70 mg/m<sup>2</sup> and carboplatin AUC = 7 every three weeks with granulocyte colony-stimulating factor (G-CSF) for six courses; and 59 patients in Arm B, treated with adjuvant doxorubicin hydrochloride 60 mg/m<sup>2</sup> and cyclophosphamide 600 mg/m<sup>2</sup> every three weeks with G-CSF for 4 courses followed by docetaxel 70 mg/m<sup>2</sup> and carboplatin AUC = 7 every three weeks with G-CSF for four courses. The mutations of BRCA 1 and 2 were not checked due to their high price, and all patients did R0 resection. The OS was defined as the time from randomisation to death, irrespective of cause, and disease-free survival (DFS) was defined as the time from randomisation to local or distant relapse or death.</p><fig id="f0001" position="float"><label>Fig. 1</label><caption><p>Consort flow chart</p></caption><graphic xlink:href="WO-21-29666-g001"/></fig></sec><sec id="sec2.2"><title>Criteria</title><p>Inclusion criteria: The female patients with age &#x0003e; 20 years, the tumour must have been determined to be HER2-negative (IHC1+ or IHC2+ and fluorescence <italic>in situ</italic> hybridisation [FISH]-negative); the tumour must have been determined to be hormone receptor-negative (ER-and PR-negative).</p><p>Exclusion criteria: T4 tumours including inflammatory BC; definitive clinical or radiologic evidence of metastatic disease; required imaging studies (computed tomography [CT] scan and bone scan) must have been performed within 90 days prior to randomisation; any previous history of ipsilateral invasive BC or ipsilateral DCIS; history of non-breast malignancies (except for in situ cancers treated only by local excision and basal cell and squamous cell carcinomas of the skin) within 5 years prior to randomisation; active or history of cardiac disease, patients known to be human immunodeficiency virus (HIV) positive, hepatitis B or hepatitis C with abnormal liver function tests; history of hospitalisation in the past 12 months for diabetes; and pregnancy or lactation at the time of study entry.</p></sec><sec id="sec2.3"><title>Statistical analyses</title><p>The analysis was done using SPSS 19 software (IBM, SPSS Inc., Chicago, IL, USA). The categorical and continuous data were analysed using &#x003c7;<sup>2</sup> and t-test, respectively. Outcomes for this study were OS, DFS, and toxicity. Comparison between OS and DFS for the two arms was checked by GraphPad Prism 5 software and the log-rank test was used to compare the Kaplan-Meier curves for OS and DFS. Also, Cox&#x02019;s proportional hazard regression analysis was used to check the effects of various parameters on the primary analysis. A <italic>p</italic>-value &#x0003c; 0.05 was considered to be statistically significant.</p></sec></sec><sec sec-type="results" id="sec3"><title>Results</title><p>A total of 119 patients were randomly enrolled to two arms (60 patients in arm A and 59 patients in arm B). The baseline characteristics of patients in the two arms are shown in <xref ref-type="table" rid="t0001">Table 1</xref>. The mean follow-up was 40 months at the time of treatment analysis. There were no significant differences between the two arms regarding the start of intervention. In the patients with lymph node involvement, a minimum of three and maximum of 15 lymph nodes were involved.</p><table-wrap id="t0001" position="float"><label>Table 1</label><caption><p>The correlation between variables in two arms</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Variables</th><th align="center" rowspan="1" colspan="1">Arm A<xref ref-type="table-fn" rid="tf1-1">*</xref> (<italic>n</italic> = 60)</th><th align="center" rowspan="1" colspan="1">Arm B<xref ref-type="table-fn" rid="tf1-2">**</xref> (<italic>n</italic> = 59)</th><th align="center" rowspan="1" colspan="1">
<italic>P</italic>-value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age, year<break/>&#x02003;Mean &#x000b1; SD<break/>&#x02003;Range<break/>&#x02003;&#x0003c; 50</td><td align="center" rowspan="1" colspan="1">45.7 &#x000b1;13.7<break/>24&#x02013;85<break/>41 (68.3)</td><td align="center" rowspan="1" colspan="1">44.1 &#x000b1;10<break/>21&#x02013;72<break/>40 (67.8)</td><td align="center" rowspan="1" colspan="1">&#x000a0;<break/>0.490<break/>&#x000a0;<break/>0.553</td></tr><tr><td align="left" rowspan="1" colspan="1">Menopausal status<break/>&#x02003;Premenopausal<break/>&#x02003;Postmenopausal</td><td align="center" rowspan="1" colspan="1">41 (68.3)<break/>19 (31.7)</td><td align="center" rowspan="1" colspan="1">39 (66.1)<break/>20 (33.9)</td><td align="center" rowspan="1" colspan="1">0.474</td></tr><tr><td align="left" rowspan="1" colspan="1">Laterality<break/>&#x02003;Right<break/>&#x02003;Left</td><td align="center" rowspan="1" colspan="1">25 (41.7)<break/>35 (58.3)</td><td align="center" rowspan="1" colspan="1">28 (47.5)<break/>31 (52.5)</td><td align="center" rowspan="1" colspan="1">0.326</td></tr><tr><td align="left" rowspan="1" colspan="1">Tumour size, cm<break/>&#x02003;&#x0003c; 2<break/>&#x02003;2&#x02013;5<break/>&#x02003;&#x0003e; 5</td><td align="center" rowspan="1" colspan="1">20 (33.3)<break/>34 (56.7)<break/>6 (10)</td><td align="center" rowspan="1" colspan="1">12 (20.3)<break/>35 (59.3)<break/>12 (20.3)</td><td align="center" rowspan="1" colspan="1">0.135</td></tr><tr><td align="left" rowspan="1" colspan="1">Lymph node invasion<break/>&#x02003;Yes<break/>&#x02003;No</td><td align="center" rowspan="1" colspan="1">24 (40)<break/>36 (60)</td><td align="center" rowspan="1" colspan="1">33 (55.9)<break/>26 (44.1)</td><td align="center" rowspan="1" colspan="1">0.060</td></tr><tr><td align="left" rowspan="1" colspan="1">Vascular invasion<break/>&#x02003;Yes<break/>&#x02003;No</td><td align="center" rowspan="1" colspan="1">12 (20)<break/>48 (80)</td><td align="center" rowspan="1" colspan="1">10 (16.9)<break/>49 (83.1)</td><td align="center" rowspan="1" colspan="1">0.424</td></tr><tr><td align="left" rowspan="1" colspan="1">Perineural invasion<break/>&#x02003;Yes<break/>&#x02003;No</td><td align="center" rowspan="1" colspan="1">5 (8.3)<break/>55 (91.7)</td><td align="center" rowspan="1" colspan="1">4 (6.8)<break/>55 (93.2)</td><td align="center" rowspan="1" colspan="1">0.511</td></tr><tr><td align="left" rowspan="1" colspan="1">Stage<break/>&#x02003;I<break/>&#x02003;II<break/>&#x02003;III</td><td align="center" rowspan="1" colspan="1">12 (20)<break/>41 (68.3)<break/>7 (11.7)</td><td align="center" rowspan="1" colspan="1">10 (16.9)<break/>33 (55.9)<break/>16 (27.1)</td><td align="center" rowspan="1" colspan="1">0.102</td></tr><tr><td align="left" rowspan="1" colspan="1">Histological Grade<break/>&#x02003;I<break/>&#x02003;II<break/>&#x02003;III</td><td align="center" rowspan="1" colspan="1">8 (13.3)<break/>23 (38.3)<break/>29 (48.3)</td><td align="center" rowspan="1" colspan="1">5 (8.5)<break/>27 (45.8)<break/>27 (45.8)</td><td align="center" rowspan="1" colspan="1">0.584</td></tr><tr><td align="left" rowspan="1" colspan="1">Margin involvement <break/>&#x02003;Yes<break/>&#x02003;No</td><td align="center" rowspan="1" colspan="1">4 (6.7)<break/>56 (93.3)</td><td align="center" rowspan="1" colspan="1">5 (8.5)<break/>54 (91.5)</td><td align="center" rowspan="1" colspan="1">0.489</td></tr><tr><td align="left" rowspan="1" colspan="1">Radiotherapy<break/>&#x02003;Yes<break/>&#x02003;No</td><td align="center" rowspan="1" colspan="1">55 (91.7)<break/>5 (8.3)</td><td align="center" rowspan="1" colspan="1">49 (83.1)<break/>10 (16.9)</td><td align="center" rowspan="1" colspan="1">0.127</td></tr><tr><td align="left" rowspan="1" colspan="1">Type of pathology<break/>&#x02003;IDC<break/>&#x02003;ILC<break/>&#x02003;MC</td><td align="center" rowspan="1" colspan="1">52 (86.7)<break/>0<break/>8 (13.3)</td><td align="center" rowspan="1" colspan="1">55 (93.2)<break/>1 (1.7)<break/>3 (5.1)</td><td align="center" rowspan="1" colspan="1">0.187</td></tr><tr><td align="left" rowspan="1" colspan="1">Ki-67, %<break/>&#x02003;Mean &#x000b1; SD<break/>&#x02003;&#x02264; 20</td><td align="center" rowspan="1" colspan="1">42.2 &#x000b1;28.4<break/>19 (31.7)</td><td align="center" rowspan="1" colspan="1">42.8 &#x000b1;25<break/>14 (23.7)</td><td align="center" rowspan="1" colspan="1">&#x000a0;<break/>0.918<break/>0.223</td></tr></tbody></table><table-wrap-foot><fn id="tf1-1"><label>*</label><p>Arm A &#x02013; docetaxel and carboplatin</p></fn><fn id="tf1-2"><label>**</label><p>Arm B &#x02013; doxorubicin hydrochloride and cyclophosphamide followed by docetaxel and carboplatin</p></fn><fn><p>SD &#x02013; standard deviation; IDC &#x02013; invasive ductal carcinoma; ILC &#x02013; invasive lobular carcinoma; MC &#x02013; medullary carcinoma</p></fn></table-wrap-foot></table-wrap><p>The two-year OS rate was 96.5% vs. 90.5%, and also the mean OS was 20.7 months vs. 21.1 months (arm A vs. arm B), and there was no significant difference between the two arms (hazard ratio [HR] 2.56, 95% CI: 0.58&#x02013;11.30; <italic>p</italic> = 0.21) (<xref ref-type="fig" rid="f0002">Fig. 2</xref>). In addition, the 5-year rate and mean OS were 91.7% vs. 81.3% and 34.4 vs. 36.4 months (arm A vs. arm B); there was no significant difference between the two arms (HR 2.04, 95% CI: 0.76&#x02013;5.43; <italic>p</italic> = 0.17). The 2-year rate and the mean DFS for arm A vs. arm B were 92.7% vs. 82.6% and 20.1 months vs. 21.2 months; there was no significant difference between the two arms (hazard ratio [HR] 2.09, 95% CI: 0.67&#x02013;6.52; <italic>p</italic> = 0.20), whereas, the 5-year rate and the mean DFS was 85% vs. 64.4% and 32.6 vs. 32 months (arm A vs. arm B); there was significant difference between the two arms (HR 2.31, 95% CI: 1.13&#x02013;4.73; <italic>p</italic> = 0.028).</p><fig id="f0002" position="float"><label>Fig. 2</label><caption><p>A) Overall survival and B) disease-free survival of patients with triple negative breast cancer</p></caption><graphic xlink:href="WO-21-29666-g002"/></fig><p>Cox&#x02019;s proportional hazard regression analysis was used to evaluate the effects of various parameters on the primary analysis. There were no unfavourable predictors for OS (<xref ref-type="table" rid="t0002">Table 2</xref>), but age and menopausal status were unfavourable predictors for DFS (<xref ref-type="table" rid="t0003">Table 3</xref>).</p><table-wrap id="t0002" position="float"><label>Table 2</label><caption><p>Multivariate survival analysis using Cox&#x02019;s regression model for affecting of variables on overall survival</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Variables</th><th align="center" rowspan="1" colspan="1"><italic>P</italic>-value</th><th align="center" rowspan="1" colspan="1">HR</th><th align="center" rowspan="1" colspan="1">95% CI</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Treatment arm, arm A vs. arm B</td><td align="center" rowspan="1" colspan="1">0.636</td><td align="center" rowspan="1" colspan="1">0.748</td><td align="center" rowspan="1" colspan="1">0.225&#x02013;2.488</td></tr><tr><td align="left" rowspan="1" colspan="1">Menopause status, pre vs. postmenopausal</td><td align="center" rowspan="1" colspan="1">0.352</td><td align="center" rowspan="1" colspan="1">0.500</td><td align="center" rowspan="1" colspan="1">0.116&#x02013;2.156</td></tr><tr><td align="left" rowspan="1" colspan="1">Age, &#x02265; 50 vs. &#x0003c; 50 years</td><td align="center" rowspan="1" colspan="1">0.085</td><td align="center" rowspan="1" colspan="1">0.277</td><td align="center" rowspan="1" colspan="1">0.064&#x02013;1.194</td></tr><tr><td align="left" rowspan="1" colspan="1">Laterality, right vs. left</td><td align="center" rowspan="1" colspan="1">0.138</td><td align="center" rowspan="1" colspan="1">0.329</td><td align="center" rowspan="1" colspan="1">0.076&#x02013;1.428</td></tr><tr><td align="left" rowspan="1" colspan="1">Tumour size, &#x0003c; 2 vs. 2&#x02013;5 or &#x0003e; 5 cm</td><td align="center" rowspan="1" colspan="1">0.275</td><td align="center" rowspan="1" colspan="1">0.581</td><td align="center" rowspan="1" colspan="1">0.219&#x02013;1.539</td></tr><tr><td align="left" rowspan="1" colspan="1">LN involvement, yes vs. no</td><td align="center" rowspan="1" colspan="1">0.805</td><td align="center" rowspan="1" colspan="1">0.830</td><td align="center" rowspan="1" colspan="1">0.188&#x02013;3.664</td></tr><tr><td align="left" rowspan="1" colspan="1">Vascular invasion, yes vs. no</td><td align="center" rowspan="1" colspan="1">0.496</td><td align="center" rowspan="1" colspan="1">2.012</td><td align="center" rowspan="1" colspan="1">0.269&#x02013;15.061</td></tr><tr><td align="left" rowspan="1" colspan="1">Perineural invasion, yes vs. no</td><td align="center" rowspan="1" colspan="1">0.756</td><td align="center" rowspan="1" colspan="1">0.694</td><td align="center" rowspan="1" colspan="1">0.070&#x02013;6.931</td></tr><tr><td align="left" rowspan="1" colspan="1">Stage, I vs. II or III</td><td align="center" rowspan="1" colspan="1">0.370</td><td align="center" rowspan="1" colspan="1">1.889</td><td align="center" rowspan="1" colspan="1">0.470&#x02013;7.597</td></tr><tr><td align="left" rowspan="1" colspan="1">Grade, I vs. II or III</td><td align="center" rowspan="1" colspan="1">0.278</td><td align="center" rowspan="1" colspan="1">0.554</td><td align="center" rowspan="1" colspan="1">0.191&#x02013;1.610</td></tr><tr><td align="left" rowspan="1" colspan="1">Margin involvement, yes vs. no</td><td align="center" rowspan="1" colspan="1">0.781</td><td align="center" rowspan="1" colspan="1">0.750</td><td align="center" rowspan="1" colspan="1">0.099&#x02013;5.695</td></tr><tr><td align="left" rowspan="1" colspan="1">Radiotherapy, yes vs. no</td><td align="center" rowspan="1" colspan="1">0.121</td><td align="center" rowspan="1" colspan="1">3.095</td><td align="center" rowspan="1" colspan="1">0.742&#x02013;12.910</td></tr><tr><td align="left" rowspan="1" colspan="1">Type of pathology, IDC vs. LC or MC</td><td align="center" rowspan="1" colspan="1">0.975</td><td align="center" rowspan="1" colspan="1">&#x02013;</td><td align="center" rowspan="1" colspan="1">&#x02013;</td></tr><tr><td align="left" rowspan="1" colspan="1">Ki-67 status, &#x02264; 20 vs. &#x0003e; 20%</td><td align="center" rowspan="1" colspan="1">0.326</td><td align="center" rowspan="1" colspan="1">1.943</td><td align="center" rowspan="1" colspan="1">0.516&#x02013;7.311</td></tr></tbody></table><table-wrap-foot><fn><p>*HRs (hazard ratios) are presented as the risk of the right-side category (i.e. right side of vs. in Parameter column) to the left-side category (i.e. left side of vs.)</p><p>LN &#x02013; lymph node; CI &#x02013; confidence interval; DC &#x02013; invasive ductal carcinoma; LC &#x02013; lobular carcinoma; MC &#x02013; medullary carcinoma. Arm A &#x02013; docetaxel and carboplatin; Arm B &#x02013; doxorubicin hydrochloride and cyclophosphamide followed by docetaxel and carboplatin</p></fn></table-wrap-foot></table-wrap><table-wrap id="t0003" position="float"><label>Table 3</label><caption><p>Multivariate survival analysis using Cox&#x02019;s regression model for affecting of variables on disease-free survival</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Variables</th><th align="center" rowspan="1" colspan="1"><italic>P</italic>-value</th><th align="center" rowspan="1" colspan="1">HR</th><th align="center" rowspan="1" colspan="1">95% CI</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Treatment arm, arm A vs. arm B</td><td align="center" rowspan="1" colspan="1">0.070</td><td align="center" rowspan="1" colspan="1">0.444</td><td align="center" rowspan="1" colspan="1">0.184&#x02013;1.070</td></tr><tr><td align="left" rowspan="1" colspan="1">Menopause status, pre vs. postmenopausal</td><td align="center" rowspan="1" colspan="1">0.022</td><td align="center" rowspan="1" colspan="1">0.283</td><td align="center" rowspan="1" colspan="1">0.097&#x02013;0.831</td></tr><tr><td align="left" rowspan="1" colspan="1">Age, &#x02265; 50 vs. &#x0003c; 50 years</td><td align="center" rowspan="1" colspan="1">0.007</td><td align="center" rowspan="1" colspan="1">0.248</td><td align="center" rowspan="1" colspan="1">0.091&#x02013;0.679</td></tr><tr><td align="left" rowspan="1" colspan="1">Laterality, right vs. left</td><td align="center" rowspan="1" colspan="1">0.603</td><td align="center" rowspan="1" colspan="1">0.779</td><td align="center" rowspan="1" colspan="1">0.303&#x02013;2.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Tumour size, &#x0003c; 2 vs. 2&#x02013;5 or &#x0003e; 5 cm</td><td align="center" rowspan="1" colspan="1">0.456</td><td align="center" rowspan="1" colspan="1">0.752</td><td align="center" rowspan="1" colspan="1">0.355&#x02013;1.592</td></tr><tr><td align="left" rowspan="1" colspan="1">LN involvement, yes vs. no</td><td align="center" rowspan="1" colspan="1">0.320</td><td align="center" rowspan="1" colspan="1">0.607</td><td align="center" rowspan="1" colspan="1">0.227&#x02013;1.624</td></tr><tr><td align="left" rowspan="1" colspan="1">Vascular invasion, yes vs. no</td><td align="center" rowspan="1" colspan="1">0.128</td><td align="center" rowspan="1" colspan="1">2.706</td><td align="center" rowspan="1" colspan="1">0.752&#x02013;9.742</td></tr><tr><td align="left" rowspan="1" colspan="1">Perineural invasion, yes vs. no</td><td align="center" rowspan="1" colspan="1">0.566</td><td align="center" rowspan="1" colspan="1">0.628</td><td align="center" rowspan="1" colspan="1">0.128&#x02013;3.071</td></tr><tr><td align="left" rowspan="1" colspan="1">Stage, I vs. II or III</td><td align="center" rowspan="1" colspan="1">0.454</td><td align="center" rowspan="1" colspan="1">1.368</td><td align="center" rowspan="1" colspan="1">0.602&#x02013;3.106</td></tr><tr><td align="left" rowspan="1" colspan="1">Grade, I vs. II or III</td><td align="center" rowspan="1" colspan="1">0.235</td><td align="center" rowspan="1" colspan="1">0.640</td><td align="center" rowspan="1" colspan="1">0.307&#x02013;1.337</td></tr><tr><td align="left" rowspan="1" colspan="1">Margin involvement, yes vs. no</td><td align="center" rowspan="1" colspan="1">0.132</td><td align="center" rowspan="1" colspan="1">2.902</td><td align="center" rowspan="1" colspan="1">0.726&#x02013;11.600</td></tr><tr><td align="left" rowspan="1" colspan="1">Radiotherapy, yes vs. no</td><td align="center" rowspan="1" colspan="1">0.114</td><td align="center" rowspan="1" colspan="1">2.399</td><td align="center" rowspan="1" colspan="1">0.810&#x02013;7.106</td></tr><tr><td align="left" rowspan="1" colspan="1">Type of pathology, DC vs. LC or MC</td><td align="center" rowspan="1" colspan="1">0.604</td><td align="center" rowspan="1" colspan="1">1.190</td><td align="center" rowspan="1" colspan="1">0.616&#x02013;2.297</td></tr><tr><td align="left" rowspan="1" colspan="1">Ki-67 status, &#x02264; 20 vs. &#x0003e; 20%</td><td align="center" rowspan="1" colspan="1">0.144</td><td align="center" rowspan="1" colspan="1">2.084</td><td align="center" rowspan="1" colspan="1">0.777&#x02013;5.588</td></tr></tbody></table><table-wrap-foot><fn><p>*HRs (hazard ratios) are presented as the risk of the right-side category (i.e. right side of vs in Parameter column) to the left-side category (i.e. left side of vs).</p><p>LN &#x02013; lymph node; CI &#x02013; confidence interval; DC &#x02013; invasive ductal carcinoma; LC &#x02013; lobular carcinoma; MC &#x02013; medullary carcinoma. Arm A &#x02013; docetaxel and carboplatin; Arm B &#x02013; doxorubicin hydrochloride and cyclophosphamide followed by docetaxel and carboplatin</p></fn></table-wrap-foot></table-wrap><p>The comparison of adverse events for the two arms is shown in <xref ref-type="table" rid="t0004">Table 4</xref>. Although thrombocytopaenia was higher in arm A compared with arm B, the difference was not significant (<italic>p</italic> &#x0003e; 0.05). Therefore, the side effects were similar in the two groups.</p><table-wrap id="t0004" position="float"><label>Table 4</label><caption><p>The adverse events for treatment regimens (two arms)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Adverse events</th><th align="center" rowspan="1" colspan="1">Arm A</th><th align="center" rowspan="1" colspan="1">Arm B</th><th align="center" rowspan="1" colspan="1"><italic>P</italic>-value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Grade 3&#x02013;4 vomiting</td><td align="center" rowspan="1" colspan="1">1 (1.7)</td><td align="center" rowspan="1" colspan="1">1 (1.7)</td><td align="center" rowspan="1" colspan="1">&#x0003e; 0.05</td></tr><tr><td align="left" rowspan="1" colspan="1">Grade 3&#x02013;4 mucositis</td><td align="center" rowspan="1" colspan="1">1 (1.7)</td><td align="center" rowspan="1" colspan="1">1 (1.7)</td><td align="center" rowspan="1" colspan="1">&#x0003e; 0.05</td></tr><tr><td align="left" rowspan="1" colspan="1">Grade 3&#x02013;4 diarrhoea</td><td align="center" rowspan="1" colspan="1">1 (1.7)</td><td align="center" rowspan="1" colspan="1">1 (1.7)</td><td align="center" rowspan="1" colspan="1">&#x0003e; 0.05</td></tr><tr><td align="left" rowspan="1" colspan="1">Grade 3&#x02013;4 neutropenia</td><td align="center" rowspan="1" colspan="1">1 (1.7)</td><td align="center" rowspan="1" colspan="1">3 (5.1)</td><td align="center" rowspan="1" colspan="1">&#x0003e; 0.05</td></tr><tr><td align="left" rowspan="1" colspan="1">Grade 3&#x02013;4 thrombocytopenia</td><td align="center" rowspan="1" colspan="1">6 (10.2)</td><td align="center" rowspan="1" colspan="1">2 (3.4)</td><td align="center" rowspan="1" colspan="1">&#x0003e; 0.05</td></tr><tr><td align="left" rowspan="1" colspan="1">Cardiotoxicity</td><td align="center" rowspan="1" colspan="1">1 (1.7)</td><td align="center" rowspan="1" colspan="1">2 (3.4)</td><td align="center" rowspan="1" colspan="1">&#x0003e; 0.05</td></tr><tr><td align="left" rowspan="1" colspan="1">Hypersensitivity reaction</td><td align="center" rowspan="1" colspan="1">1 (1.7)</td><td align="center" rowspan="1" colspan="1">1 (1.7)</td><td align="center" rowspan="1" colspan="1">&#x0003e; 0.05</td></tr><tr><td align="left" rowspan="1" colspan="1">Peripheral neuropathy</td><td align="center" rowspan="1" colspan="1">2 (3.4)</td><td align="center" rowspan="1" colspan="1">1 (1.7)</td><td align="center" rowspan="1" colspan="1">&#x0003e; 0.05</td></tr><tr><td align="left" rowspan="1" colspan="1">Sepsis</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">1 (1.7)</td><td align="center" rowspan="1" colspan="1">&#x0003e; 0.05</td></tr></tbody></table><table-wrap-foot><fn><p>Arm A &#x02013; docetaxel and carboplatin, Arm B &#x02013; doxorubicin hydrochloride and cyclophosphamide followed by docetaxel and carboplatin</p></fn></table-wrap-foot></table-wrap></sec><sec sec-type="discussion" id="sec4"><title>Discussion</title><p>Both arms in this study had carboplatin because we wanted to check the efficacy of adding of an anthracycline (doxorubicin) to the taxane regimen in stage I-IIITNBC patients that more patients were stages I and II (88.3% arm A and 72.9% arm B). The results showed that adding anthracycline to the chemotherapy regimen did not increase the 5-year OS (HR 2.04, 95% CI: 0.76&#x02013;5.43; <italic>p</italic> = 0.17) and DFS (HR 2.31, 95% CI: 1.13&#x02013;4.73; <italic>p</italic> = 0.028). Although grade 3-4 neutropaenia and cardiotoxicity was more in anthracycline-based regimen and also thrombocytopaenia in the regimen without anthracycline, the differences were not significant. Patients suffering from TNBC have a poor prognosis mainly because no standard treatment is currently available [<xref rid="cit0016" ref-type="bibr">16</xref>]. Anthracyclines and taxanes are the most active and widely used chemotherapeutic agents in hormone receptor-negative patients for treating BC and those whose disease progresses while they are taking hormone therapy [<xref rid="cit0017" ref-type="bibr">17</xref>]. These agents are commonly used in the adjuvant setting, either in combination or sequentially [<xref rid="cit0018" ref-type="bibr">18</xref>]. Anthracycline use in early-stage BC has been steadily declining, especially for patients with stage I/II or HER2-positive disease, and the overall analysis reported that 80% of chemotherapies were anthracycline-based in these patients from 2000 to 2010. Then, the use of anthracycline-based regimens reduced 20% in stage I/II and 6% in stage III patients, while non-anthracycline regimens (cyclophosphamide, methotrexate, and fluorouracil) increased from 5% to 35% [<xref rid="cit0019" ref-type="bibr">19</xref>]; one study from Giordano <italic>et al</italic>. [<xref rid="cit0020" ref-type="bibr">20</xref>] confirmed these results. Multiple trials in the 1980s and 1990s demonstrated that an anthracycline-based chemotherapy regimen was associated with lower rates of BC recurrence and improved survival when compared with non-anthracycline regimens [<xref rid="cit0012" ref-type="bibr">12</xref>]. The addition of taxanes to anthracycline-based chemotherapy as adjuvant therapy decreases the risk of recurrence (4.6%) and overall mortality (3.2%) [<xref rid="cit0021" ref-type="bibr">21</xref>]. One trial [<xref rid="cit0022" ref-type="bibr">22</xref>] compared docetaxel plus cyclophosphamide (TC) with a first-generation anthracycline regimen (doxorubicin plus cyclophosphamide, or AC) and reported superior OS for the patients treated with TC. The patients treated with TC had more fever and neutropaenia (5% vs. 2.5%), but congestive heart failure developed in one patient treated with AC and none with TC. Smith <italic>et al</italic>. [<xref rid="cit0023" ref-type="bibr">23</xref>] demonstrated that anthracyclines increased the risk of clinical cardiotoxicity (5.43 fold), subclinical cardiotoxicity (6.25 fold), any cardiotoxicity (2.27 fold), and the risk of cardiac death (4.94 fold) compared with non-anthracycline regimens. The trial by Chen <italic>et al</italic>. [<xref rid="cit0024" ref-type="bibr">24</xref>] reported that patients with neoadjuvant treatment of TNBC or HER2-positive with docetaxel, anthracycline, and cyclophosphamide (TEC) had a higher rate of neutropaenia and leukopaenia. TEC treatment had a better survival outcome and a trend of higher complete response rate compared with TC in this trial setting, especially in TNBC subtype, which deserves further validation. On univariate analysis [<xref rid="cit0025" ref-type="bibr">25</xref>], patients who had received prior adjuvant chemotherapy with anthracyclines had a significantly lower probability of response than patients who did not: 43% vs. 58% (<italic>p</italic> = 0.02). The patients who did not receive adjuvant chemotherapy had a longer survival time than the patients previously treated with anthracycline-based (21.1 vs. 15.8 months) adjuvant chemotherapy. Also, multivariate analysis confirmed adjuvant chemotherapy with anthracyclines to be among the strongest prognostic factors associated with both poor PFS and OS. Piccart-Gebhart <italic>et al</italic>. [<xref rid="cit0026" ref-type="bibr">26</xref>] reported that taxanes were significantly worse compared with single-agent anthracyclines in terms of PFS, but not in terms of response rates or survival. Taxane-based combinations were significantly better than anthracycline-based combinations in terms of response rates and PFS, but not in terms of survival. A taxane-based treatment regimen may be a better option than a combined taxane/anthracycline regimen for patients with advanced BC because it produces equivalent clinical outcomes and has lower toxicity compared to other similar regimens [<xref rid="cit0027" ref-type="bibr">27</xref>]. Five randomised studies compared anthracyclines (doxorubicin, epirubicin, pegylated liposomal doxorubicin) vs. other drugs, but it did not reach the statistical significance for the endpoints of response rate, time to progression, and OS, suggesting a minor role for anthracycline in the therapeutic strategy of pretreated metastatic BC patients [<xref rid="cit0028" ref-type="bibr">28</xref>&#x02013;<xref rid="cit0032" ref-type="bibr">32</xref>]. Although doxorubicin has become one of the most effective chemotherapeutic agents, it was noted early on that its use was complicated by the development of heart failure [<xref rid="cit0033" ref-type="bibr">33</xref>, <xref rid="cit0034" ref-type="bibr">34</xref>]. Multiple large cohort trials and meta-analysis studies showed that the addition of a taxane to an anthracycline-based regimen in the adjuvant setting has improved the PFS and OS in patients with early BC. According to these, the use of anthracyclines as initial chemotherapy in early BC may continue to be replaced by taxane-based and novel regimens in the future [<xref rid="cit0035" ref-type="bibr">35</xref>]. We need a prospective, more advanced trial with clearly more rigorous reporting and data monitoring (a larger group of patients).</p><p>In conclusion, less progression was found with arm A as compared to arm B. Therefore, the addition of anthracyclines such as doxorubicin hydrochloride did jot increase OS and DFS in TNBC patients. Due to the number of TNBC patients in stages I and II, we can easily omit anthracyclines in the treatment of these patients.</p></sec></body><back><ack><p content-type="COI-statement">The authors declare no conflict of interest.</p></ack><ref-list><title>References</title><ref id="cit0001"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kr&#x000f6;ger</surname><given-names>N</given-names></name><name><surname>Achterrath</surname><given-names>W</given-names></name><name><surname>Hegewisch-Becker</surname><given-names>S</given-names></name><name><surname>Mross</surname><given-names>K</given-names></name><name><surname>Zander</surname><given-names>AR</given-names></name></person-group><article-title>Current options in treatment of anthracycline-resistant breast cancer</article-title><source>Cancer Treat Rev</source><year>1999</year><volume>25</volume><fpage>279</fpage><lpage>91</lpage><pub-id pub-id-type="pmid">10544072</pub-id></element-citation></ref><ref id="cit0002"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wahba</surname><given-names>HA</given-names></name><name><surname>El-Hadaad</surname><given-names>HA</given-names></name></person-group><article-title>Current approaches in treatment of triple-negative breast cancer</article-title><source>Cancer Biol Med</source><year>2015</year><volume>12</volume><fpage>106</fpage><lpage>16</lpage><pub-id pub-id-type="pmid">26175926</pub-id></element-citation></ref><ref id="cit0003"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bauer</surname><given-names>KR</given-names></name><name><surname>Brown</surname><given-names>M</given-names></name><name><surname>Cress</surname><given-names>RD</given-names></name><name><surname>Parise</surname><given-names>C.A</given-names></name><name><surname>Caggiano</surname><given-names>V</given-names></name></person-group><article-title>Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry</article-title><source>Cancer</source><year>2007</year><volume>109</volume><fpage>1721</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">17387718</pub-id></element-citation></ref><ref id="cit0004"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hurvitz</surname><given-names>S</given-names></name><name><surname>Mead</surname><given-names>M</given-names></name></person-group><article-title>Triple-negative breast cancer: advancements in characterization and treatment approach</article-title><source>Curr Opin Obstet Gynecol</source><year>2016</year><volume>28</volume><fpage>59</fpage><lpage>69</lpage><pub-id pub-id-type="pmid">26694831</pub-id></element-citation></ref><ref id="cit0005"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dent</surname><given-names>R</given-names></name><name><surname>Trudeau</surname><given-names>M</given-names></name><name><surname>Pritchard</surname><given-names>KI</given-names></name><etal/></person-group><article-title>Triple-negative breast cancer: clinical features and patterns of recurrence</article-title><source>Clin Cancer Res</source><year>2007</year><volume>13</volume><fpage>4429</fpage><lpage>34</lpage><pub-id pub-id-type="pmid">17671126</pub-id></element-citation></ref><ref id="cit0006"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gl&#x000fc;ck</surname><given-names>S</given-names></name><name><surname>Ross</surname><given-names>JS</given-names></name><name><surname>Royce</surname><given-names>M</given-names></name><name><surname>McKenna</surname><given-names>EF</given-names><suffix>Jr</suffix></name><name><surname>Perou</surname><given-names>CM</given-names></name><name><surname>Avisar</surname><given-names>E</given-names></name><name><surname>Wu</surname><given-names>L</given-names></name></person-group><article-title>TP53 genomics predict higher clinical and pathologic tumor response in operable early-stage breast cancer treated with docetaxel-capecitabine &#x000b1; trastuzumab</article-title><source>Breast Cancer Res Treat</source><year>2012</year><volume>132</volume><fpage>781</fpage><lpage>91</lpage><pub-id pub-id-type="pmid">21373875</pub-id></element-citation></ref><ref id="cit0007"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liedtke</surname><given-names>C</given-names></name><name><surname>Mazouni</surname><given-names>C</given-names></name><name><surname>Hess</surname><given-names>KR</given-names></name><etal/></person-group><article-title>Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer</article-title><source>J Clin Oncol</source><year>2008</year><volume>26</volume><fpage>1275</fpage><lpage>81</lpage><pub-id pub-id-type="pmid">18250347</pub-id></element-citation></ref><ref id="cit0008"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lehmann</surname><given-names>BD</given-names></name><name><surname>Jovanovi&#x00107;</surname><given-names>B</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><etal/></person-group><article-title>Refinement of triple-negative breast cancer molecular subtypes: implications for neoadjuvant chemotherapy selection</article-title><source>PLoS One</source><year>2016</year><volume>11</volume><fpage>e0157368</fpage><pub-id pub-id-type="pmid">27310713</pub-id></element-citation></ref><ref id="cit0009"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Portha</surname><given-names>H</given-names></name><name><surname>Jankowski</surname><given-names>C</given-names></name><name><surname>Cortet</surname><given-names>M</given-names></name><name><surname>Desmoulins</surname><given-names>I</given-names></name><name><surname>Martin</surname><given-names>E</given-names></name><name><surname>Lorgis</surname><given-names>V</given-names></name><name><surname>Arnould</surname><given-names>L</given-names></name><name><surname>Coutant</surname><given-names>C</given-names></name></person-group><article-title>Non-metastatic triple-negative breast cancer in 2016: Definitions and management</article-title><source>Gynecol Obstet Fertil</source><year>2016</year><volume>44</volume><fpage>492</fpage><lpage>504</lpage><pub-id pub-id-type="pmid">27451066</pub-id></element-citation></ref><ref id="cit0010"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rampurwala</surname><given-names>MM</given-names></name><name><surname>Rocque</surname><given-names>GB</given-names></name><name><surname>Burkard</surname><given-names>ME</given-names></name></person-group><article-title>Update on adjuvant chemotherapy for early breast cancer</article-title><source>Breast Cancer (Auckl)</source><year>2014</year><volume>8</volume><fpage>125</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">25336961</pub-id></element-citation></ref><ref id="cit0011"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamamoto</surname><given-names>Y</given-names></name><name><surname>Iwase</surname><given-names>H</given-names></name></person-group><article-title>Clinicopathological features and treatment strategy for triple-negative breast cancer</article-title><source>Int J Clin Oncol</source><year>2010</year><volume>15</volume><fpage>341</fpage><lpage>51</lpage><pub-id pub-id-type="pmid">20632057</pub-id></element-citation></ref><ref id="cit0012"><label>12</label><element-citation publication-type="journal"><collab>Early Breast Cancer Trialists&#x02019; Collaborative Group (EBCTCG)</collab><article-title>Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials</article-title><source>Lancet</source><year>2005</year><volume>365</volume><fpage>1687</fpage><lpage>717</lpage><pub-id pub-id-type="pmid">15894097</pub-id></element-citation></ref><ref id="cit0013"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moreno-Aspitia</surname><given-names>A</given-names></name><name><surname>Perez</surname><given-names>EA</given-names></name></person-group><article-title>Treatment options for breast cancer resistant to anthracycline and taxane</article-title><source>Mayo Clin Proc</source><year>2009</year><volume>84</volume><fpage>533</fpage><lpage>45</lpage><pub-id pub-id-type="pmid">19483170</pub-id></element-citation></ref><ref id="cit0014"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Joensuu</surname><given-names>H</given-names></name><name><surname>Gligorov</surname><given-names>J</given-names></name></person-group><article-title>Adjuvant treatments for triple-negative breast cancers</article-title><source>Ann Oncol</source><year>2012</year><volume>23</volume><fpage>vi40</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">23012301</pub-id></element-citation></ref><ref id="cit0015"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pai</surname><given-names>VB</given-names></name><name><surname>Nahata</surname><given-names>MC</given-names></name></person-group><article-title>Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention</article-title><source>Drug Saf</source><year>2000</year><volume>22</volume><fpage>263</fpage><lpage>302</lpage><pub-id pub-id-type="pmid">10789823</pub-id></element-citation></ref><ref id="cit0016"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Shi</surname><given-names>Y</given-names></name><name><surname>Yuan</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Classical CMF regimen as adjuvant chemotherapy for triple-negative breast cancer may be more effective compared with anthracycline or taxane-based regimens</article-title><source>Med Oncol</source><year>2012</year><volume>29</volume><fpage>547</fpage><lpage>53</lpage><pub-id pub-id-type="pmid">21528408</pub-id></element-citation></ref><ref id="cit0017"><label>17</label><element-citation publication-type="webpage"><collab>National Comprehensive Cancer Network Web site NCCN Practice Guidelines in Oncology-v.1.2009</collab><source>Breast Cancer</source><comment><ext-link ext-link-type="uri" xlink:href="http://www.nccn.org/professionals/physician_gls/PDF/breast.pdf">http://www.nccn.org/professionals/physician_gls/PDF/breast.pdf</ext-link><ext-link ext-link-type="uri" xlink:href="http://www.nccn.org/professionals/physician_gls/PDF/breast.pdf">http://www.nccn.org/professionals/physician_gls/PDF/breast.pdf</ext-link></comment><comment>Accessed May 1, 2009</comment></element-citation></ref><ref id="cit0018"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dean-Colomb</surname><given-names>W</given-names></name><name><surname>Esteva</surname><given-names>FJ</given-names></name></person-group><article-title>Emerging agents in the treatment of anthracycline- and taxane-refractory metastatic breast cancer</article-title><source>Semin Oncol</source><year>2008</year><volume>35</volume><fpage>S31</fpage><lpage>8</lpage><comment>quiz S40</comment><pub-id pub-id-type="pmid">18410797</pub-id></element-citation></ref><ref id="cit0019"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Helwick</surname><given-names>C</given-names></name></person-group><article-title>Anthracycline Use Steadily Declining in Early Breast Cancer Population</article-title><source>ASCO Post</source><year>2012</year><fpage>3</fpage></element-citation></ref><ref id="cit0020"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giordano</surname><given-names>SH</given-names></name><name><surname>Lin</surname><given-names>YL</given-names></name><name><surname>Kuo</surname><given-names>YF</given-names></name><name><surname>Hortobagyi</surname><given-names>GN</given-names></name><name><surname>Goodwin</surname><given-names>JS</given-names></name></person-group><article-title>Decline in the use of anthracyclines for breast cancer</article-title><source>J Clin Oncol</source><year>2012</year><volume>30</volume><fpage>2232</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">22614988</pub-id></element-citation></ref><ref id="cit0021"><label>21</label><element-citation publication-type="journal"><collab>Early Breast Cancer Trialists&#x02019; Collaborative Group (EBCTCG)</collab><person-group person-group-type="author"><name><surname>Peto</surname><given-names>R</given-names></name><name><surname>Davies</surname><given-names>C</given-names></name></person-group><article-title>Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials</article-title><source>Lancet</source><year>2012</year><volume>379</volume><fpage>432</fpage><lpage>44</lpage><pub-id pub-id-type="pmid">22152853</pub-id></element-citation></ref><ref id="cit0022"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>SE</given-names></name><name><surname>Savin</surname><given-names>MA</given-names></name><name><surname>Holmes</surname><given-names>FA</given-names></name><etal/></person-group><article-title>Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer</article-title><source>J Clin Oncol</source><year>2006</year><volume>24</volume><fpage>5381</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">17135639</pub-id></element-citation></ref><ref id="cit0023"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>LA</given-names></name><name><surname>Cornelius</surname><given-names>VR</given-names></name><name><surname>Plummer</surname><given-names>CJ</given-names></name><name><surname>Levitt</surname><given-names>G</given-names></name><name><surname>Verrill</surname><given-names>M</given-names></name><name><surname>Canney</surname><given-names>P</given-names></name><name><surname>Jones</surname><given-names>A</given-names></name></person-group><article-title>Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials</article-title><source>BMC Cancer</source><year>2010</year><volume>10</volume><fpage>337</fpage><pub-id pub-id-type="pmid">20587042</pub-id></element-citation></ref><ref id="cit0024"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Ye</surname><given-names>G</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name><etal/></person-group><article-title>Superior outcome after neoadjuvant chemotherapy with docetaxel, anthracycline, and cyclophosphamide versus docetaxel plus cyclophosphamide: results from the NATT trial in triple negative or HER2 positive breast cancer</article-title><source>Breast Cancer Res Treat</source><year>2013</year><volume>142</volume><fpage>549</fpage><lpage>58</lpage><pub-id pub-id-type="pmid">24292815</pub-id></element-citation></ref><ref id="cit0025"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Venturini</surname><given-names>M</given-names></name><name><surname>Bruzzi</surname><given-names>P</given-names></name><name><surname>Del Mastro</surname><given-names>L</given-names></name><etal/></person-group><article-title>Effect of adjuvant chemotherapy with or without anthracyclines on the activity and efficacy of first-line cyclophosphamide, epidoxorubicin, and fluorouracil in patients with metastatic breast cancer</article-title><source>J Clin Oncol</source><year>1996</year><volume>14</volume><fpage>764</fpage><lpage>73</lpage><pub-id pub-id-type="pmid">8622022</pub-id></element-citation></ref><ref id="cit0026"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Piccart-Gebhart</surname><given-names>MJ</given-names></name><name><surname>Burzykowski</surname><given-names>T</given-names></name><name><surname>Buyse</surname><given-names>M</given-names></name><etal/></person-group><article-title>Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer</article-title><source>J Clin Oncol</source><year>2008</year><volume>26</volume><fpage>1980</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">18421049</pub-id></element-citation></ref><ref id="cit0027"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>R</given-names></name><name><surname>Han</surname><given-names>S</given-names></name><name><surname>Duan</surname><given-names>C</given-names></name><etal/></person-group><article-title>Role of taxane and anthracycline combination regimens in the management of advanced breast cancer: a meta-analysis of randomized trials</article-title><source>Medicine (Baltimore)</source><year>2015</year><volume>94</volume><fpage>e803</fpage><pub-id pub-id-type="pmid">25929935</pub-id></element-citation></ref><ref id="cit0028"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Henderson</surname><given-names>IC</given-names></name><name><surname>Allegra</surname><given-names>JC</given-names></name><name><surname>Woodcock</surname><given-names>T</given-names></name><name><surname>Wolff</surname><given-names>S</given-names></name><name><surname>Bryan</surname><given-names>S</given-names></name><name><surname>Cartwright</surname><given-names>K</given-names></name><name><surname>Dukart</surname><given-names>G</given-names></name><name><surname>Henry</surname><given-names>D</given-names></name></person-group><article-title>Randomized clinical trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer</article-title><source>J Clin Oncol</source><year>1989</year><volume>7</volume><fpage>560</fpage><lpage>71</lpage><pub-id pub-id-type="pmid">2468745</pub-id></element-citation></ref><ref id="cit0029"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bontenbal</surname><given-names>M</given-names></name><name><surname>Andersson</surname><given-names>M</given-names></name><name><surname>Wildiers</surname><given-names>J</given-names></name><etal/></person-group><article-title>Doxorubicin vs epirubicin, report of a second-line randomized phase II/III study in advanced breast cancer. EORTC Breast Cancer Cooperative Group</article-title><source>Br J Cancer</source><year>1998</year><volume>77</volume><fpage>2257</fpage><lpage>63</lpage><pub-id pub-id-type="pmid">9649142</pub-id></element-citation></ref><ref id="cit0030"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Joensuu</surname><given-names>H</given-names></name><name><surname>Holli</surname><given-names>K</given-names></name><name><surname>Heikkinen</surname><given-names>M</given-names></name><name><surname>Suonio</surname><given-names>E</given-names></name><name><surname>Aro</surname><given-names>AR</given-names></name><name><surname>Hietanen</surname><given-names>P</given-names></name><name><surname>Huovinen</surname><given-names>R</given-names></name></person-group><article-title>Combination chemotherapy versus single-agent therapy as first- and second-line treatment in metastatic breast cancer: a prospective randomized trial</article-title><source>J Clin Oncol</source><year>1998</year><volume>16</volume><fpage>3720</fpage><lpage>30</lpage><pub-id pub-id-type="pmid">9850014</pub-id></element-citation></ref><ref id="cit0031"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Norris</surname><given-names>B</given-names></name><name><surname>Pritchard</surname><given-names>KI</given-names></name><name><surname>James</surname><given-names>K</given-names></name><etal/></person-group><article-title>Phase III comparative study of vinorelbine combined with doxorubicin versus doxorubicin alone in disseminated metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA8</article-title><source>J Clin Oncol</source><year>2000</year><volume>18</volume><fpage>2385</fpage><lpage>94</lpage><pub-id pub-id-type="pmid">10856098</pub-id></element-citation></ref><ref id="cit0032"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keller</surname><given-names>AM</given-names></name><name><surname>Mennel</surname><given-names>RG</given-names></name><name><surname>Georgoulias</surname><given-names>VA</given-names></name><etal/></person-group><article-title>Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer</article-title><source>J Clin Oncol</source><year>2004</year><volume>22</volume><fpage>3893</fpage><lpage>901</lpage><pub-id pub-id-type="pmid">15459210</pub-id></element-citation></ref><ref id="cit0033"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lefrak</surname><given-names>EA</given-names></name><name><surname>Pitha</surname><given-names>J</given-names></name><name><surname>Rosenheim</surname><given-names>S</given-names></name><name><surname>Gottlieb</surname><given-names>JA</given-names></name></person-group><article-title>A clinicopathologic analysis of adriamycin cardiotoxicity</article-title><source>Cancer</source><year>1973</year><volume>32</volume><fpage>302</fpage><lpage>14</lpage><pub-id pub-id-type="pmid">4353012</pub-id></element-citation></ref><ref id="cit0034"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Von Hoff</surname><given-names>DD</given-names></name><name><surname>Layard</surname><given-names>MW</given-names></name><name><surname>Basa</surname><given-names>P</given-names></name><name><surname>Davis</surname><given-names>HL</given-names><suffix>Jr</suffix></name><name><surname>Von Hoff</surname><given-names>AL</given-names></name><name><surname>Rozencweig</surname><given-names>M</given-names></name><name><surname>Muggia</surname><given-names>FM</given-names></name></person-group><article-title>Risk factors for doxorubicin-induced congestive heart failure</article-title><source>Ann Intern Med</source><year>1979</year><volume>91</volume><fpage>710</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">496103</pub-id></element-citation></ref><ref id="cit0035"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Greene</surname><given-names>J</given-names></name><name><surname>Hennessy</surname><given-names>B</given-names></name></person-group><article-title>The role of anthracyclines in the treatment of early breast cancer</article-title><source>J Oncol Pharm Pract</source><year>2015</year><volume>21</volume><fpage>201</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">24769570</pub-id></element-citation></ref></ref-list></back></article>